整理:黄玉庭;排版:景胜杰
投稿:jingshengjie@dxy.cn
参考文献:
1、Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer(CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(4):436-446. doi:10.1016/S1470-2045(15)70064-1.
2、Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628-637. doi:10.1038/s41591-018-0009-7.
3、Wang, B., Sun, T., Zhao, Y. et al. A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun 13, 4025(2022). https://doi.org/10.1038/s41467-022-31704-7.
4、Li, DD., Tao, Zh., Wang, BY. et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. npj Breast Cancer 8, 110(2022). https://doi.org/10.1038/s41523-022-00462-6.
5、Carey LA, Loirat D, Punie K, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022;8(1):72. Published 2022 Jun 9. doi:10.1038/s41523-022-00439-5.
联系客服